Effects of Pioglitazone, a Peroxisome Proliferator–Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat
Open Access
- 25 October 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 113 (2) , 349-357
Abstract
Peroxisome proliferator–activated receptors (PPARs) are ligand-activated transcription factors, which belong to the nuclear receptor superfamily. Some PPARγ agonists, such as pioglitazone, and dual PPARγ/PPARα agonists, such as muraglitazar, induced urothelial bladder tumors in rats but not in mice. In this study, we investigated the early effects in the urine and bladder of rats treated with pioglitazone to evaluate the possible relation between urinary solids formation and urothelial cytotoxicity and regenerative proliferation. In a 4-week experiment, treatment of rats with 16 mg/kg pioglitazone induced cytotoxicity and necrosis of the urothelial superficial layer, with increased cell proliferation measured by bromodeoxyuridine labeling index and hyperplasia by histology. It also produced alterations in urinary solid formation, especially calcium-containing crystals and calculi. PPARγ agonists (pioglitazone and troglitazone) in vitro reduced rat urothelial cell proliferation and induced uroplakin synthesis, a specific differentiation marker in urothelial cells. Our data support the hypothesis that the bladder tumors produced in rats by pioglitazone are related to the formation of urinary solids. This strongly supports the previous conclusion in studies with muraglitazar that this is a rat-specific phenomenon and does not pose a urinary bladder cancer risk to humans treated with these agents.Keywords
This publication has 25 references indexed in Scilit:
- Effects of PPAR agonists on proliferation and differentiation in human urotheliumExperimental and Toxicologic Pathology, 2008
- Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting EventToxicologic Pathology, 2008
- Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urotheliumToxicology and Applied Pharmacology, 2007
- Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPARα/γ Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of ActionToxicologic Pathology, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Effects of PPARγ and Combined Agonists on the Urinary Tract of Rats and Other SpeciesToxicological Sciences, 2005
- Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urotheliumin vivoBiomarkers, 2005
- Role of PPAR γ and EGFR signalling in the urothelial terminal differentiation programmeJournal of Cell Science, 2004
- Effect of epidermal growth factor and transforming growth factor β1 on growth and invasive potentials of newly established rat bladder carcinoma cell linesInternational Journal of Cancer, 1993
- Randomization of Animals by Computer Program for Toxicity StudiesJournal of the American College of Toxicology, 1984